A large-scale study analysing whole genome sequencing (WGS) data from cancer patients provides new insight into the genetic basis of tumour development and progression. The study, one of the largest of its kind, examined thousands of cancer genomes across multiple tumour types, enabling a more comprehensive view of cancer biology than previously possible.
By sequencing the entire genome of tumours, researchers were able to identify a wide range of genetic alterations, including mutations, structural variants and mutational patterns. These patterns, often referred to as mutational signatures, reflect the biological and environmental processes that contribute to cancer, such as DNA repair defects, cellular metabolism, and external exposures.
The scale of the dataset allowed the identification of both known and previously unrecognised mutational signatures. In particular, the study reported dozens of new signatures that had not been detectable in smaller cohorts, highlighting additional and still poorly understood mechanisms involved in cancer development.
Importantly, the findings demonstrate the value of WGS in capturing the full genomic landscape of tumours in a single analysis. Compared to targeted sequencing approaches, WGS provides a more complete and integrated view of cancer genomes, which can inform diagnosis, prognosis, and treatment decisions.
The study also highlights the importance of large, well-annotated datasets that link genomic information with clinical outcomes. Such resources enable more accurate interpretation of genomic changes and support the translation of genomic data into clinical care.
________________________________________________________________________________________________________________
Article can be accessed on: TheScientist
Image credit:©iStock, ArtemisDiana
